Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2021 Sep;29(9):5283-5292.
doi: 10.1007/s00520-021-06099-8. Epub 2021 Mar 3.

Continuous recording of vital signs with a wearable device in pediatric patients undergoing chemotherapy for cancer-an operational feasibility study

Christa Koenig  1 , Roland A Ammann  2   3 , Claudia E Kuehni  4 , Jochen Roessler  2 , Eva Brack  2
Affiliations
Observational Study

Continuous recording of vital signs with a wearable device in pediatric patients undergoing chemotherapy for cancer-an operational feasibility study

Christa Koenig et al. Support Care Cancer. 2021 Sep.

Abstract

Purpose: Pediatric patients with cancer are at high risk for severe infections. Infections can trigger changes of vital signs long before clinical symptoms arise. Continuous recording may detect such changes earlier than discrete measurements. We aimed to assess the feasibility of continuous recording of vital signs by a wearable device (WD) in pediatric patients undergoing chemotherapy for cancer.

Methods: In this prospective, observational single-center study, pediatric patients under chemotherapy wore the Everion® WD for 14 days. The predefined patient-specific goal was heart rate recorded in good quality during ≥18/24 h per day, on ≥7 consecutive days. The predefined criterion to claim feasibility was ≥15/20 patients fulfilling this patient-specific goal.

Results: Twenty patients were included (median age, 6 years; range, 2-16). Six patients aged 3-16 years fulfilled the patient-specific goal. Quality of heart rate recording was good during 3992 of 6576 (61%) hours studied and poor during 300 (5%) hours, and no data was recorded during 2284 (35%) hours. Eighteen of 20 participants indicated that this WD is acceptable to measure vital signs in children under chemotherapy.

Conclusion: The predefined feasibility criterion was not fulfilled. This was mainly due to important compliance problems and independent of the WD itself. However, continuous recording of vital signs was possible across a very wide age range in pediatric patients undergoing chemotherapy for cancer. We recommend to study feasibility in the Everion® again, plus in further WDs, applying measures to enhance compliance.

Trial registration: ClinicalTrials.gov (NCT04134429) on October 22, 2019.

Keywords: Continuous recording; Pediatric oncology; Recording vital signs; Supportive care; Wearable device.

PubMed Disclaimer

Conflict of interest statement

Jochen Roessler reports personal fees from Pierre Fabre, Roche, Novartis, SOBI, Bayer, Jazz Pharmaceutical and Servier, all outside the submitted work. The other authors declare no competing interests.

Figures

Fig. 1
Fig. 1
The Everion® device, placed on the upper leg of a 10-month-old and on the upper arm of a 3-year-old child. (Parents gave informed consent for publication of these photographs)
Fig. 2
Fig. 2
a Primary outcome measure—recording of heart rate. b Recording of heart rate variability. Legend: green, good data quality; red, poor data quality; white, no data recorded; gray, no study days; days ≥18 h, number of days with at least 18 hours of good data quality per patient; ID, patient ID
Fig. 3
Fig. 3
Histogram and quality assignment of heart rate, plus proportion of time with poor quality assignment of heart rate variability according to heart rate
Fig. 4
Fig. 4
Histogram and quality assignment of respiration rate. Legend: green, good data quality; red, poor data quality
Fig. 5
Fig. 5
Histogram and quality assignment of core temperature (calculated). Legend: green, good data quality; red, poor data quality
See this image and copyright information in PMC

References

    1. Lehrnbecher T, Robinson P, Fisher B, Alexander S, Ammann RA, Beauchemin M, Carlesse F, Groll AH, Haeusler GM, Santolaya M, Steinbach WJ, Castagnola E, Davis BL, Dupuis LL, Gaur AH, Tissing WJE, Zaoutis T, Phillips R, Sung L. Guideline for the management of fever and neutropenia in children with cancer and hematopoietic stem-cell transplantation recipients: 2017 Update. J Clin Oncol. 2017;35(18):2082–2094. doi: 10.1200/JCO.2016.71.7017. - DOI - PubMed
    1. Fletcher M, Hodgkiss H, Zhang S, Browning R, Hadden C, Hoffman T, Winick N, McCavit TL. Prompt administration of antibiotics is associated with improved outcomes in febrile neutropenia in children with cancer. Pediatr Blood Cancer. 2013;60(8):1299–1306. doi: 10.1002/pbc.24485. - DOI - PubMed
    1. Rosa RG, Goldani LZ. Cohort study of the impact of time to antibiotic administration on mortality in patients with febrile neutropenia. Antimicrob Agents Chemother. 2014;58(7):3799–3803. doi: 10.1128/AAC.02561-14. - DOI - PMC - PubMed
    1. Salstrom JL, Coughlin RL, Pool K, Bojan M, Mediavilla C, Schwent W, Rannie M, Law D, Finnerty M, Hilden J. Pediatric patients who receive antibiotics for fever and neutropenia in less than 60 min have decreased intensive care needs. Pediatr Blood Cancer. 2015;62(5):807–815. doi: 10.1002/pbc.25435. - DOI - PMC - PubMed
    1. Koenig C, Schneider C, Morgan JE, Ammann RA, Sung L, Phillips B. Association of time to antibiotics and clinical outcomes in patients with fever and neutropenia during chemotherapy for cancer: a systematic review. Support Care Cancer. 2020;28(3):1369–1384. doi: 10.1007/s00520-019-04961-4. - DOI - PubMed

Publication types

Associated data